Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice

• Published in: Breast cancer research and treatment Vol. 133; no. 1; pp. 301 - 310
• Main Authors: Weycker, Derek, Barron, Rich, Edelsberg, John, Kartashov, Alex, Lyman, Gary H.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.05.2012; Springer; Springer Nature B.V
• Subjects: Adult; Aged; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - standards; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - epidemiology; Breast Neoplasms - pathology; Cancer; Cancer research; Cancer therapies; Chemotherapy; Dose-Response Relationship, Drug; Drug dosages; Epidemiology; Female; Gynecology. Andrology. Obstetrics; Humans; Mammary gland diseases; Medical sciences; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Staging; Oncology; Pharmacology. Drug treatments; Reference Standards; Retrospective Studies; Treatment Outcome; Tumors; Women; United States; North America; America; Outcomes research; Chemotherapy; Breast cancer; Human; Breast disease; Prognosis; Low dose; Intensification; Early stage; Malignant tumor; Research; Epidemiology; Incidence; Mammary gland diseases; Treatment; Adult; Female; Woman; Cancer

Chemotherapy is widely used to treat early stage breast cancer (ESBC). Reductions and delays in dose administered—e.g., due to advanced age or febrile neutropenia (FN)—are generally believed to increase risk of disease progression and reduce survival. Little is known about incidence of reduced chemo...